Peptide Profile

Thymogen

Glu-Trp / Oglufanide Immunomodulatory Dipeptide

Research Only10 sourcesShop Thymogen

Overview

Composition

Synthetic dipeptide composed of L-glutamic acid and L-tryptophan (L-Glu-L-Trp), also known as oglufanide or glutamyltryptophan

Mechanism of Action

Acts as an immunomodulatory short peptide studied for effects on T-lymphocyte differentiation/proliferation, neutrophil/monocyte/NK-cell function, cytokine balance, and hematopoietic recovery signaling

Primary Effects

Explored for immune resilience, secondary immunodeficiency contexts, infection recovery, and hematopoietic support, with strongest published support coming from Russian and preclinical/in vitro literature

Discovery & Background

Developed from thymic peptide research; Glu-Trp was isolated from thymic preparations and later synthesized as Thymogen

Reported in Russian immunomodulator research beginning in the late 20th century, with later work exploring chiral peptide analogs, cytokine modulation, and orally active peptidomimetic derivatives

Registered/used in Russia in some formulations; not FDA-approved in the United States

Research Overview

Evidence includes in vitro immune-cell/cytokine studies, animal models, Russian clinical literature, and drug-development references to oglufanide; broad Western clinical validation is limited

01
Thymogen is described as L-Glu-L-Trp with immunostimulating properties
02
Published chemistry/immunology work describes effects on T-lymphocytes, neutrophils, monocytes, NK cells, and cellular/humoral immune regulation
03
In vitro studies report modulation of inflammatory cytokines and endothelial adhesion markers under inflammatory stimulation
04
Clinical development history includes investigation under the name oglufanide
05
No FDA approval and limited high-quality contemporary randomized evidence for common wellness/research uses

Research-only or region-specific pharmaceutical status depending on jurisdiction

Safety Considerations

Monitoring

CBC with differential when immune or hematologic effects are relevant
Infection symptoms and inflammatory markers
Medication interactions in immunocompromised or autoimmune contexts
Autoimmune flare or unusual immune symptoms

Side Effects

Reported/possible

Published tolerability data are limited outside regional clinical literature
Mild local irritation has been reported
Headache, fatigue, or transient immune-like symptoms

Data limitations

Limited contemporary controlled safety data outside regional use
Unknown effects in pregnancy, breastfeeding, autoimmune disease, or transplant/immunosuppressed populations

Contraindications

Known hypersensitivity to Glu-Trp products
Use caution in autoimmune disease, active malignancy, transplant status, or immunosuppressive therapy
Pregnancy and breastfeeding due to insufficient safety data

Educational Notice

Thymogen/Glu-Trp is an immunomodulatory dipeptide with regional pharmaceutical history and published preclinical/in vitro support, but it is not FDA-approved and lacks broad contemporary validation for most research/wellness uses. Immune-active compounds should be used only with qualified medical oversight.

References